When the immune system's trained defenses fail against advanced kidney cancer, oncologists have long faced an unanswered question: which second-line treatment to reach for next. A Phase II trial presented at the European Society for Medical Oncology Congress in October has begun to answer that question, finding that a combination of lenvatinib and everolimus extended progression-free survival by more than five months compared to cabozantinib alone among ninety patients whose cancers had resisted immunotherapy. In a field where head-to-head comparisons are rare, this evidence offers something m
Medical Xpress
· Oct 20, 2025
· health
· 1 min de lectura
High
Verificación: Verificado
Dual therapy outperforms cabozantinib in advanced kidney cancer after immunotherapy failure
The trial involved 90 patients with advanced metastatic kidney cancer whose disease had progressed despite prior immunotherapy treatment.
◉
Health & Medicine
8412 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% coincidencia
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% coincidencia
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% coincidencia
Cobertura Relacionada
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
This is a medical research article about kidney cancer treatment efficacy, not a geopolitical matter requiring international relations analysis.
Escalation Risk
N/A
Confidence
HIGH
Lente Económico
📈
Lenvatinib plus everolimus demonstrates superior efficacy over cabozantinib for immunotherapy-resistant kidney cancer, potentially reshaping treatment protocols and market dynamics in oncology therapeutics.
Market Signal
mixed
Confidence
HIGH
Pharmaceutical Manufacturing
Oncology/Cancer Treatment
Healthcare Services
Medical Devices and Diagnostics
Health Insurance
Patients with advanced kidney cancer resistant to immunotherapy gain access to more effective treatment options, potentially extending progression-free survival by 5.5 months on average. This may reduce out-of-pocket costs through improved outcomes and fewer treatment switches, though drug costs and insurance coverage remain considerations.
FDA may accelerate approval or expand indications for lenvatinib-everolimus combination therapy. Healthcare systems and insurers may update treatment guidelines and formularies to prioritize this combination as second-line therapy. Payers may negotiate pricing based on superior efficacy data. Regulatory bodies may require similar head-to-head trials for other cancer drug combinations.